These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 17220607)

  • 21. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A
    Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
    [No Abstract]   [Full Text] [Related]  

  • 23. Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
    Breccia M
    Nat Rev Clin Oncol; 2010 Oct; 7(10):557-8. PubMed ID: 20877419
    [No Abstract]   [Full Text] [Related]  

  • 24. [New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].
    Liu H; Chen XG
    Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):561-3. PubMed ID: 17236546
    [No Abstract]   [Full Text] [Related]  

  • 25. Chronic myeloid leukemia: the race is yet to be won.
    Cortes J
    CMAJ; 2012 May; 184(8):857-8. PubMed ID: 22271914
    [No Abstract]   [Full Text] [Related]  

  • 26. [Treatment of imatinib-intolerant or -resistant CML patients].
    Kimura S
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():304-8. PubMed ID: 23133972
    [No Abstract]   [Full Text] [Related]  

  • 27. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.
    Koca E; Cetiner D; Goker H; Aksu S; Ozcebe OI; Haznedaroglu IC; Turgan C
    Clin Nephrol; 2005 Oct; 64(4):324-6. PubMed ID: 16240908
    [No Abstract]   [Full Text] [Related]  

  • 28. Two new agents effective in Gleevec-resistant CML.
    Cancer Biol Ther; 2004 Dec; 3(12):1198-9. PubMed ID: 15864854
    [No Abstract]   [Full Text] [Related]  

  • 29. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Looking beyond imatinib: next line of targeted drugs for CML shows promise.
    Hampton T
    JAMA; 2006 Jan; 295(4):369-70. PubMed ID: 16434621
    [No Abstract]   [Full Text] [Related]  

  • 31. David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies.
    Druker BJ
    J Clin Oncol; 2003 Dec; 21(23 Suppl):239s-245s. PubMed ID: 14645403
    [No Abstract]   [Full Text] [Related]  

  • 32. A hope for the future.
    Silver RT
    Cancer Invest; 2003 Jun; 21(3):486. PubMed ID: 12901295
    [No Abstract]   [Full Text] [Related]  

  • 33. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
    Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
    [No Abstract]   [Full Text] [Related]  

  • 34. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Leuk Lymphoma; 2007 Apr; 48(4):802-4. PubMed ID: 17454640
    [No Abstract]   [Full Text] [Related]  

  • 35. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.
    Sawyers CL
    Cancer Cell; 2002 Feb; 1(1):13-5. PubMed ID: 12086882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. STI571: a gene product-targeted therapy for leukemia.
    Mauro MJ; Druker BJ
    Curr Oncol Rep; 2001 May; 3(3):223-7. PubMed ID: 11296132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Part II: management of resistance to imatinib in chronic myeloid leukaemia.
    Apperley JF
    Lancet Oncol; 2007 Dec; 8(12):1116-1128. PubMed ID: 18054881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tyrosine kinase inhibitors: the next generation.
    Fricker J
    Lancet Oncol; 2006 Aug; 7(8):621. PubMed ID: 16900596
    [No Abstract]   [Full Text] [Related]  

  • 39. STI571: a magic bullet?
    Verweij J; Judson I; van Oosterom A
    Eur J Cancer; 2001 Oct; 37(15):1816-9. PubMed ID: 11576833
    [No Abstract]   [Full Text] [Related]  

  • 40. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
    Murphy M; Close J; Lottenberg R; Rajasekhar A
    Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.